Oct 16, 2026Weekly roundup

Incyte's radiolabeled INCB161734 mass balance study active, not recruiting

Phase 1 trial testing a single oral dose of [14C]-INCB161734 in healthy men is underway, with primary completion expected October 2026.

Incyte Corporation had one trial update of note this week, a Phase 1 pharmacokinetics study.

Incyte Corporation sponsors this open-label Phase 1 study assessing the mass balance, pharmacokinetics, and metabolite profiles of a single oral dose of radiolabeled INCB161734 in healthy male participants.¹ The study's status is active, not recruiting, with an actual start date of 2026-09-18 and estimated primary completion on 2026-10-15. The trial enrolled 10 participants.¹

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.

Sources

A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 6, 2026. Story written by readthrough.
A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck. ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Oct 23, 2026. Story written by readthrough.
Ruxolitinib for Premalignant Breast Disease ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Oct 16, 2026. Story written by readthrough.
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Oct 16, 2026. Story written by readthrough.

About